CAMP4 THERAPEUTICS CORP (CAMP)
Health Care · biotechnology · NASDAQ
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapies to upregulate gene expression and restore protein levels for patients with genetic diseases.
What CAMP4 THERAPEUTICS CORP does
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics to treat genetic diseases by upregulating gene expression. Its proprietary RAP Platform identifies regulatory RNAs (regRNAs) that control protein-coding genes, allowing for the design of antisense oligonucleotides (ASOs) that increase mRNA and protein production to address haploinsufficient disorders. The company's lead candidate, CMP-002, is currently in development for SYNGAP1-related disorder.
Recent developments
The company received regulatory clearance in Australia and Argentina for a Phase 1/2 clinical trial of CMP-002, which is expected to initiate in the fourth quarter of 2026. Additionally, the company secured $50.1 million in gross proceeds from the second closing of a private placement in August 2026, extending its cash runway through the end of 2028.
From CAMP4 THERAPEUTICS CORP's filing of 2026-08-13.
Themes: RNA-targeting therapeutics, gene expression modulation, CNS diseases, genetic medicine, rare disease drug development
Fundamentals
- Price$3.70 as of 2026-10-08 close
- Market cap$232M as of 2026-08-12 (share count; price 2026-10-08)
- 1-year return+4.5% 2025-10-08 close $3.54 → 2026-10-08 close $3.70
- P/En/a negative earnings
- Net margin-2298.5% FY2025, SEC XBRL
- ROE-168.5% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+5.6% as of 2026-09-03
- Revenue CAGR (3y)+216.1% SEC XBRL
- Beta1.48 as of 2026-09-03
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CAMP compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CAMP4 THERAPEUTICS CORP looks technically
CAMP4 THERAPEUTICS CORP (CAMP) is trading 18.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 64 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-07-31, breaking below its recent trading range. It is 52.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 18.0% below its 200-day average, the long-term trend line — a long-term downtrend | -18.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.18 | $4.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.51 | $4.51 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 4.1517. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 64 trading days ago — a "death cross", a bearish long-term signal | 64 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 15, below the 25 that marks a real trend) | 14.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 41, neither overbought (above 70) nor oversold (below 30) | 40.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($3.51 to $4.32) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 23.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $7.75 | $7.75 |
|---|---|---|
| From the 52-week high | it is 52.3% below its 52-week high (its highest price of the past year) | -52.3% |
| Above the 52-week low | it is 42.3% above its 52-week low (its lowest price of the past year) | +42.3% |
| Below the 52-week high | it is 52.3% below its highest point of the past year | 52.3% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-07-31, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 39 trading days ago | 39 sessions |
| All-time high | its highest closing price on record is $12.30 (set on 2024-10-14) | $12.30 |
| Given back of the 52-week move | over the past year its closes ranged ($2.79 to $7.13), and it has given back well over two thirds of its rise from last year’s low — 79% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.31 to $4.45. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 79.0% |
| From the all-time high | it is 69.9% below its all-time high | -69.9% |
| Nearest price level | it is sitting right on a support level at $3.68 — a price it turned at three times since 2025-09-10, most recently on 2026-09-23. Since 2024-10-11 it has 6 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $1.30 (set on 2025-06-20) | $1.30 |
| Above the all-time low | it is 183.5% above its all-time low | +183.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 78% of it) | 22nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3356 between its high and its low — about 9.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3356 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.65 and $4.33 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.65 – $3.99 – $4.33 |
| Typical daily range (% of price) | its price moves about 9.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.1% |
| Stretch from the 200-day average | it is trading 2.4 daily ranges below its 200-day average price (18.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.80× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 7.5% since the prior reading | +7.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.04 toward buy |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.0% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.0% |
|---|---|---|
| Open gap | it gapped 3.8% above the previous close 49 sessions ago and has not traded back through the level it left behind at 3.27 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.8% |
| Gap filled | a 2.8% gap down opened on 2026-10-07 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -7.73% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 16.9 percentage points (the stock lost 15.9% while the market gained 1.0%) | -16.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 15.5 percentage points (the stock lost 11.7% while the market gained 3.8%) | -15.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 35.0 percentage points (the stock lost 17.6% while the market gained 17.5%) | -35.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 10.5 percentage points (the stock gained 4.5% while the market gained 15.0%) | -10.5% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.4% of the share price, which is taken to mean a barrier that gives way easily. | -16.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.62 — a volume-weighted average of daily closes over 183 sessions, not a true tick-by-tick VWAP. | -19.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.21 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -12.1% |
Head and shoulders, bearish — broke down · entry $4.07 · 62 sessions in
Price levels it has turned at before
CAMP last closed at $3.70 on 2026-10-08. Since 2024-10-11 it has turned at 6 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.68 | Support | 0.5% below the last close | turned there three times · 2025-09-10 to 2026-09-23 |
| $3.81 | Resistance | 3.1% above the last close | turned there twice · 2025-10-10 to 2026-05-05 |
| $3.89 | Resistance | 5.1% above the last close | turned there twice · 2026-03-03 to 2026-03-30 |
| $3.50 | Support | 5.4% below the last close | turned there three times · 2025-01-14 to 2026-02-17 |
| $3.99 | Resistance | 7.8% above the last close | turned there twice · 2025-03-11 to 2025-03-21 |
| $2.88 | Support | 22.2% below the last close | turned there twice · 2025-10-17 to 2026-07-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $4.15.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $2.55 and $3.16 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $4.15.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$10.57 range $6.00 – $15.00; median $9.00
Analyst estimates, as of 2026-10-07. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CAMP
- Consensus EPS estimate-$0.2044 next reporting period, as of 2026-10-07
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company has incurred significant operating losses and requires substantial additional capital to fund clinical development, which may lead to dilution or program delays.","The success of the company's proprietary RAP Platform and clinical-stage candidate CMP-002 is unproven and subject to the inherent risks of clinical trials and regulatory approval."]
What changed in the latest 10-Q
AI-assisted comparison of CAMP's 10-Q filed 2026-08-13 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-13) adds a sentence in the CMP-002 preclinical discussion stating a single dose of CMP-002 produced a statistically significant improvement in both seizure threshold and severity of chemically induced tonic-clonic seizures in SYNGAP1 haploinsufficient mice.
- Newer filing (2026-08-13) states the company received clearance from Australia's Therapeutic Goods Administration and Argentina's Administración Nacional de Medicamentos, Alimentos y Tecnología Médica to initiate the Phase 1/2 clinical trial of CMP-002.
- Newer filing (2026-08-13) states the company has submitted additional regulatory filings in the European Union and United Kingdom to support broader enrollment.
- Newer filing (2026-08-13) adds a sentence that the company intends to initiate the Phase 1/2 clinical trial in the fourth quarter of 2026.
- Newer filing (2026-08-13) adds a sentence stating that subsequent to June 30, 2026, the company received net proceeds of $46.9 from the Second Closing of the Private Placement.
- Newer filing (2026-08-13) changes net losses disclosure to $51.9 million and $25.0 million for the six months ended June 30, 2026 and 2025, respectively.
- Newer filing (2026-08-13) changes accumulated deficit disclosure to $344.0 million as of June 30, 2026.
- Newer filing (2026-08-13) changes research collaboration and license revenue disclosure to $24.6 million through June 30, 2026.
- Removed:
- Older filing (2026-05-07) states the company had submitted its first regulatory filing in Australia to enable initiation of a clinical trial, with additional global regulatory filings planned in 2026.
- Older filing (2026-05-07) states that pending regulatory clearance, the company intends to initiate the global Phase 1/2 clinical trial in the second half of 2026.
- Older filing (2026-05-07) states net losses were $18.3 million and $12.4 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-07) states accumulated deficit was $310.5 million as of March 31, 2026.
- Older filing (2026-05-07) states research collaboration and license revenue was $22.8 million through March 31, 2026.
- Reworded:
- Newer filing (2026-08-13) refers to the private placement as having an Initial Closing in September 2025 and a Second Closing in August 2026, while the older filing (2026-05-07) refers to it as the 'September 2025 private placement' with no mention of a second closing.
- Newer filing (2026-08-13) describes additional discovery programs as 'other CNS indications', while older filing (2026-05-07) describes them as 'other DEE indications'.
- Newer filing (2026-08-13) refers to 'Special Note Regarding Forward-Looking Statements and Industry Data' while older filing (2026-05-07) refers to 'Special Note Regarding Forward-Looking Statements'.
- Newer filing (2026-08-13) tail of MD&A section appears truncated mid-sentence ('Ou') compared to older filing, which continues with text about net losses fluctuating and additional public company costs.
- Notes:
- The newer filing's MD&A text is truncated mid-sentence at 'Ou' immediately after the accumulated deficit sentence; text after that point is unavailable for comparison.
- The newer filing defines the Second Closing of the Private Placement as occurring in August 2026 and states net proceeds of $46.9 but omits a unit (e.g., million) in the provided text.
Risk Factors
- Added:
- Newer filing (2026-08-13) states cash and cash equivalents were $86.4 million as of June 30, 2026.
- Newer filing (2026-08-13) states net proceeds of $46.9 million were received from the Second Closing of the Private Placement in August 2026.
- Newer filing (2026-08-13) states that cash and cash equivalents as of June 30, 2026, together with the August 2026 private placement proceeds, are estimated to fund operations through the end of 2028.
- Removed:
- Older filing (2026-05-07) included a risk factor about orphan drug designation for CMP-001 and CMP-002, which is not present in the newer filing.
- Notes:
- The newer filing text for the Risk Factors section is truncated mid-sentence (ends at 'which ma'), so the full newer Risk Factors section could not be compared.
- The older filing excerpt includes subsequent items (Item 2 through Item 6) and exhibits that are outside the Risk Factors section and were not compared.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
5 open-market purchases and 6 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-045 buys ($99051) · 6 sells ($3M) — 4 buying, 2 selling insiders
- Last 180 days · read to 2026-10-045 buys ($99051) · 6 sells ($3M) — 4 buying, 2 selling insiders
Cluster buying: 4 different insiders reported open-market purchases (SEC code P) of CAMP within a 30-day window between 2026-08-03 and 2026-08-31. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-31. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CAMP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding CAMP as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 6,910,773
- Reported value $30,200,078
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CAMP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CAMP had 992,712 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CAMP had 1.58% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.63 days to cover at the same settlement.
- Reported short interest (shares) 992,712
- Short interest (% of shares outstanding) 1.58%
- Prior settlement (shares) 1,186,689
- Reported change -16.35%
- Days to cover (reported) 3.63
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ionis Pharmaceuticals (IONS)
- Alnylam Pharmaceuticals (ALNY)
- Sarepta Therapeutics (SRPT)
- Wave Life Sciences (WVE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CAMP vs…
CAMP4 THERAPEUTICS CORP is found in…
CAMP ranks in…
Frequently asked questions
What does CAMP4 THERAPEUTICS CORP (CAMP) do?
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics to treat genetic diseases by upregulating gene expression. Its proprietary RAP Platform identifies regulatory RNAs (regRNAs) that control protein-coding genes, allowing for the design of antisense oligonucleotides (ASOs) that increase mRNA and protein production to address haploinsufficient disorders.
What sector is CAMP4 THERAPEUTICS CORP (CAMP) in?
CAMP4 THERAPEUTICS CORP (CAMP) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CAMP4 THERAPEUTICS CORP's (CAMP) competitors?
Notable peers of CAMP4 THERAPEUTICS CORP (CAMP) include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Sarepta Therapeutics and Wave Life Sciences. This peer set is informational only — not financial advice.
Is CAMP4 THERAPEUTICS CORP (CAMP) overbought or oversold right now?
CAMP4 THERAPEUTICS CORP (CAMP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 41, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CAMP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.